BIOMARKER:

TET2 mutation

A2 | Sensitive

C2 | Sensitive

C3 | Sensitive

D | Sensitive

A2 | Resistant

C2 | Resistant

C3 | Resistant

D | Resistant

Acute Myelogenous Leukemia

Myelodysplastic Syndrome

Peripheral T-cell Lymphoma

Chronic Myelomonocytic Leukemia

Lymphoma

T Cell Non-Hodgkin Lymphoma

ruxolitinib

TET2 mutation|Myelodysplastic Syndrome|ruxolitinib

azacitidine

TET2 mutation|Myelodysplastic Syndrome|azacitidine

TET2 mutation|Acute Myelogenous Leukemia|azacitidine

TET2 mutation|Chronic Myelomonocytic Leukemia|azacitidine

HAG + azacitidine

TET2 mutation|Acute Myelogenous Leukemia|HAG + azacitidine

venetoclax

TET2 mutation|Acute Myelogenous Leukemia|venetoclax

sintilimab

TET2 mutation|Myelodysplastic Syndrome|sintilimab

cytarabine

TET2 mutation|Acute Myelogenous Leukemia|cytarabine

quizartinib

TET2 mutation|Acute Myelogenous Leukemia|quizartinib

venetoclax + decitabine/cedazuridine

TET2 mutation|Acute Myelogenous Leukemia|venetoclax + decitabine/cedazuridine

CHOP

TET2 mutation|Peripheral T-cell Lymphoma|CHOP

azacitidine + romidepsin

TET2 mutation|Lymphoma|azacitidine + romidepsin

CHOP + azacitidine oral

TET2 mutation|Peripheral T-cell Lymphoma|CHOP + azacitidine oral

pembrolizumab

TET2 mutation|Myelodysplastic Syndrome|pembrolizumab

talazoparib

TET2 mutation|Acute Myelogenous Leukemia|talazoparib

cytarabine/daunorubicin liposomal formulation

TET2 mutation|Acute Myelogenous Leukemia|cytarabine/daunorubicin liposomal formulation

lenalidomide

TET2 mutation|T Cell Non-Hodgkin Lymphoma|lenalidomide

gemtuzumab ozogamicin

TET2 mutation|Acute Myelogenous Leukemia|gemtuzumab ozogamicin